Cargando…

A Study of Use of “PORT” Catheter in Patients with Cancer: A Single-Center Experience

BACKGROUND: Effective and reliable venous access is one of the cornerstones of modern medical therapy in oncology. MATERIALS AND METHODS: This is a prospective observational study, which collected data of patients who require “PORT” catheter insertion for any cancer, at a tertiary care oncology hosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Madabhavi, Irappa, Patel, Apurva, Sarkar, Malay, Anand, Asha, Panchal, Harsha, Parikh, Sonia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395272/
https://www.ncbi.nlm.nih.gov/pubmed/28469510
http://dx.doi.org/10.1177/1179554917691031
_version_ 1783229850268467200
author Madabhavi, Irappa
Patel, Apurva
Sarkar, Malay
Anand, Asha
Panchal, Harsha
Parikh, Sonia
author_facet Madabhavi, Irappa
Patel, Apurva
Sarkar, Malay
Anand, Asha
Panchal, Harsha
Parikh, Sonia
author_sort Madabhavi, Irappa
collection PubMed
description BACKGROUND: Effective and reliable venous access is one of the cornerstones of modern medical therapy in oncology. MATERIALS AND METHODS: This is a prospective observational study, which collected data of patients who require “PORT” catheter insertion for any cancer, at a tertiary care oncology hospital in Ahmadabad, Gujarat, India, during a 2-year period. AIMS AND OBJECTIVES: The main objective of this study was to study the various complications and outcomes related to “PORT” catheters. RESULTS: “PORT” catheter was inserted in 100 patients and was most commonly used in solid malignancies (n = 86, 86%), followed by hematologic malignancies (n = 14, 14%). Among the solid malignancies, breast cancer (38, 38%) was the most common underlying disease, whereas among the hematologic malignancies, acute lymphoblastic leukemia (6, 6%) was the most common underlying disease for “PORT” catheter insertion. Chemotherapy was started on the first day of “PORT” catheter in 74% of patients in the “PORT” study group. The various complications developed in the “PORT” study group in the descending order are as follows: 4 patients (4%) developed early infection (⩽30 days after “PORT” placement), 4 (4%) late infection (⩾30 days after “PORT” placement), 4 (4%) bloodstream infection, 2 (2%) local skin infection at the “PORT” insertion site, 2 (2%) dislodgment of the “PORT” catheter, 2 (2%) fracture of the “PORT” catheter, and 1 recurrent pleural effusion. One patient (1%) developed thrombosis as the complication of “PORT” catheter insertion. CONCLUSIONS: The most disturbing aspect of treatment for a patient with cancer is multiple painful venipunctures made for administration of cytotoxic agents, antibiotics, blood products, and nutritional supplements. The focus of this prospective observational research is to study the various underlying diseases for which “PORT” catheter is needed in different solid and hematologic malignancies and the various complications and outcomes in pediatric and adult patients with cancer.
format Online
Article
Text
id pubmed-5395272
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-53952722017-05-03 A Study of Use of “PORT” Catheter in Patients with Cancer: A Single-Center Experience Madabhavi, Irappa Patel, Apurva Sarkar, Malay Anand, Asha Panchal, Harsha Parikh, Sonia Clin Med Insights Oncol Original Research BACKGROUND: Effective and reliable venous access is one of the cornerstones of modern medical therapy in oncology. MATERIALS AND METHODS: This is a prospective observational study, which collected data of patients who require “PORT” catheter insertion for any cancer, at a tertiary care oncology hospital in Ahmadabad, Gujarat, India, during a 2-year period. AIMS AND OBJECTIVES: The main objective of this study was to study the various complications and outcomes related to “PORT” catheters. RESULTS: “PORT” catheter was inserted in 100 patients and was most commonly used in solid malignancies (n = 86, 86%), followed by hematologic malignancies (n = 14, 14%). Among the solid malignancies, breast cancer (38, 38%) was the most common underlying disease, whereas among the hematologic malignancies, acute lymphoblastic leukemia (6, 6%) was the most common underlying disease for “PORT” catheter insertion. Chemotherapy was started on the first day of “PORT” catheter in 74% of patients in the “PORT” study group. The various complications developed in the “PORT” study group in the descending order are as follows: 4 patients (4%) developed early infection (⩽30 days after “PORT” placement), 4 (4%) late infection (⩾30 days after “PORT” placement), 4 (4%) bloodstream infection, 2 (2%) local skin infection at the “PORT” insertion site, 2 (2%) dislodgment of the “PORT” catheter, 2 (2%) fracture of the “PORT” catheter, and 1 recurrent pleural effusion. One patient (1%) developed thrombosis as the complication of “PORT” catheter insertion. CONCLUSIONS: The most disturbing aspect of treatment for a patient with cancer is multiple painful venipunctures made for administration of cytotoxic agents, antibiotics, blood products, and nutritional supplements. The focus of this prospective observational research is to study the various underlying diseases for which “PORT” catheter is needed in different solid and hematologic malignancies and the various complications and outcomes in pediatric and adult patients with cancer. SAGE Publications 2017-02-23 /pmc/articles/PMC5395272/ /pubmed/28469510 http://dx.doi.org/10.1177/1179554917691031 Text en © The Author(s) 2017 http://creativecommons.org/licenses/by-nc/3.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License (http://www.creativecommons.org/licenses/by-nc/3.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page(https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Madabhavi, Irappa
Patel, Apurva
Sarkar, Malay
Anand, Asha
Panchal, Harsha
Parikh, Sonia
A Study of Use of “PORT” Catheter in Patients with Cancer: A Single-Center Experience
title A Study of Use of “PORT” Catheter in Patients with Cancer: A Single-Center Experience
title_full A Study of Use of “PORT” Catheter in Patients with Cancer: A Single-Center Experience
title_fullStr A Study of Use of “PORT” Catheter in Patients with Cancer: A Single-Center Experience
title_full_unstemmed A Study of Use of “PORT” Catheter in Patients with Cancer: A Single-Center Experience
title_short A Study of Use of “PORT” Catheter in Patients with Cancer: A Single-Center Experience
title_sort study of use of “port” catheter in patients with cancer: a single-center experience
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395272/
https://www.ncbi.nlm.nih.gov/pubmed/28469510
http://dx.doi.org/10.1177/1179554917691031
work_keys_str_mv AT madabhaviirappa astudyofuseofportcatheterinpatientswithcancerasinglecenterexperience
AT patelapurva astudyofuseofportcatheterinpatientswithcancerasinglecenterexperience
AT sarkarmalay astudyofuseofportcatheterinpatientswithcancerasinglecenterexperience
AT anandasha astudyofuseofportcatheterinpatientswithcancerasinglecenterexperience
AT panchalharsha astudyofuseofportcatheterinpatientswithcancerasinglecenterexperience
AT parikhsonia astudyofuseofportcatheterinpatientswithcancerasinglecenterexperience
AT madabhaviirappa studyofuseofportcatheterinpatientswithcancerasinglecenterexperience
AT patelapurva studyofuseofportcatheterinpatientswithcancerasinglecenterexperience
AT sarkarmalay studyofuseofportcatheterinpatientswithcancerasinglecenterexperience
AT anandasha studyofuseofportcatheterinpatientswithcancerasinglecenterexperience
AT panchalharsha studyofuseofportcatheterinpatientswithcancerasinglecenterexperience
AT parikhsonia studyofuseofportcatheterinpatientswithcancerasinglecenterexperience